Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial
- 1 July 2016
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 177, 1-8
Abstract
No abstract availableKeywords
Funding Information
- Abbott Laboratories
- Medtronic
- Bristol-Myers Squibb
- St. Jude Medical
- Eli Lilly and Company
- Boehringer Ingelheim
- Pfizer
- Takeda Pharmaceutical Company
- Sanofi
- GlaxoSmithKline
- Medicines Company
- Merck
- Daiichi-Sankyo
- Novartis
- Servier
- Roche
- Janssen Pharmaceutica
- Bayer
- Merck Sharp and Dohme United Kingdom
- AstraZeneca
This publication has 13 references indexed in Scilit:
- 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)JACC, 2012
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)European Heart Journal, 2011
- Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary SyndromesJACC, 2010
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2009
- Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trialAmerican Heart Journal, 2009
- Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting StentsNew England Journal of Medicine, 2007
- Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel PretreatmentThe ISAR-REACT 2 Randomized TrialJAMA, 2006
- Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirinEuropean Heart Journal, 2006
- Glycoprotein IIb/IIIa and P2Y12receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responsesPlatelets, 2005
- Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trialsThe Lancet, 2002